Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...

Apricus Biosciences' (APRI) main drug is Vitaros; a topical treatment for erectile dysfunction (ED) that has found partners in many countries but is waiting for Abbott to start Canadian sales and get ...

SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...

SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the outcome of ...

SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq: APRI), announced today that Health Canada has granted marketing approval for Vitaros ® as a first-line therapy for ...

Apricus Biosciences, Inc. ( APRI) recently announced that its erectile dysfunction (ED) drug, Vitaros, has been approved under the European Decentralized Procedure (DCP). Apricus, along with its ...

EAST WINDSOR, N.J.--(BUSINESS WIRE)--October 20, 2008--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative treatments based on the NexACT ® technology, announced today that it met with the Food and ...

Apricus Biosciences Inc APRI receded 67.4 percent Friday and continued down Tuesday after the U.S. Food and Drug Administration issued a response letter for Vitaros. The FDA declined to approve the ...